Efficacy
squamous cell carcinoma, PD, HPV-negative tumors
SQUAMOUS CELL CARCINOMA, DISEASE PROGRESSION, DISEASE, DISEASE PROGRESSION
Median follow-up was 23.8 months (range: 3.9–26.2). There was no disease progression during chemoradiotherapy. Two months after brachytherapy completion, the ORR according to the RECIST 1.1 criteria was 93.8% (95% confidence interval (CI): 69.8–99.8%): eight patients (50%) had a complete response (CR) and seven patients (43.75%) had a partial response (PR); one patient (6.25%) had disease progression and underwent subsequent surgery. At the last follow-up, a total of 12 patients had responded (11 CR, 1 PR; ORR 75%, 95% CI: [47.6;92.7]; hereafter grouped as “progression-free”, PF); while, four patients had progression of the disease (hereafter grouped as PD): three patients while on nivolumab maintenance (at 3, 4, and 5 months after treatment initiation), and one patient after completion of nivolumab maintenance (at eight months after treatment initiation). Of note, two patients with HPV-negative tumors of squamous cell carcinoma histology achieved a complete response to treatment. All patients that progressed had squamous cell carcinoma. Disease progression was loco-regional in three patients and loco-regional plus distant in one patient. Three patients died (18.75%) due to disease progression. Two-year PFS was 75% (95% CI: 56.5–99.5%) (Fig. 